BioNTech has struck an agreement with Rwanda and Senegal to open the first manufacturing facilities producing messenger RNA for vaccines in Africa, as part of the company’s push into the continent.
The German biotech said construction would begin in mid-2022, but declined to say in which of the two countries.
“Together, we will work on developing a regional manufacturing network to support the access to vaccines manufactured in Africa, for Africa,” BioNTech’s chief executive and co-founder Ugur Sahin said in a statement. “Our goal is . . . to establish sustainable vaccine production capabilities to jointly improve medical care in Africa.”
您已阅读21%（644字），剩余79%（2486字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。